CDMO Capacity and Availability: What Sponsors Should Ask

CDMO capacity generally refers to the manufacturing and operational resources available to support projects.

That can involve more than whether a piece of equipment is physically available.

Capacity may depend on:

• manufacturing suites
• production lines
• equipment
• personnel
• analytical resources
• quality resources
• development laboratories
• fill finish lines
• project-management bandwidth
• raw-material availability
• campaign scheduling
• cleaning or changeover requirements

A facility can therefore have the technical capability to perform the work without having near-term availability for another project.

This is an important distinction.

Capability asks:

Can the facility perform this type of work?

Capacity asks:

Does the facility have enough available resources to perform the work within the required timeframe?

A CDMO may clearly have the technical capability but be fully booked.

Another manufacturer may have available capacity but lack the equipment, scale, experience, or technical services required by the program.

Sponsors need both.

Manufacturing is often tied directly to larger development milestones.

For an early-stage biotech company, delays may affect:

• IND-enabling work
• clinical material availability
• regulatory submissions
• trial initiation
• fundraising milestones
• investor expectations
• internal development plans

For later-stage programs, manufacturing timing can affect validation, launches, supply commitments, or commercial inventory.

A technically attractive CDMO with an unacceptable start date may therefore create more risk than a slightly less preferred manufacturer that can realistically support the required schedule.

Sponsors sometimes focus only on the date they need GMP material.

That skips several steps.

Before manufacturing begins, the project may require:

• contract execution
• confidentiality agreements
• technical transfer
• process development
• analytical transfer
• method development
• raw-material procurement
• engineering work
• documentation
• quality review
• batch planning

A facility may have a manufacturing slot available six months from now, but the project may need several months of preparation before that slot can actually be used.

Ask about the full path to manufacturing, not only the batch date.

A statement such as:

"We have availability in Q2"

can mean many different things.

Does it mean the project can begin in Q2?

Does it mean technical transfer can begin?

Does it mean an engineering batch can run?

Does it mean a GMP slot is available?

Does the slot depend on another client's schedule changing?

Sponsors should clarify exactly what the manufacturer means when discussing capacity.

Useful questions include:

• What is the earliest realistic project kickoff?
• When could technical transfer begin?
• When is the first manufacturing slot available?
• Is that slot currently reserved?
• What milestones must be completed before it can be confirmed?
• How much flexibility exists if our timeline changes?

Specific questions produce more useful answers.

Large CDMOs may operate multiple facilities.

One site may have limited availability while another site within the same organization has more room.

But moving the project to a different facility may also change:

• available equipment
• manufacturing scale
• technical expertise
• regulatory history
• geography
• support services
• project economics

The sponsor needs to know where the work would actually take place.

A facility may appear to have capacity overall while the particular equipment needed for the project is heavily booked.

This can happen with specialized assets such as:

• bioreactors
• fill finish lines
• lyophilizers
• containment suites
• high-potency manufacturing areas
• viral-vector suites
• specialized analytical equipment

For programs that depend on specific equipment, ask about availability at that level.

General facility capacity may not tell the whole story.

A CDMO that is well suited for a small clinical batch may not be the best option for future commercial production.

Likewise, a large commercial manufacturing facility may not be ideal for an early program.

Sponsors should think about what kind of capacity they actually need.

Questions may include:

• What batch sizes can the facility support?
• Is the site optimized for clinical or commercial manufacturing?
• Can the program scale within the same facility?
• Would a later-stage scale-up require a transfer?
• How much capacity would be available if demand increases?

Not every early-stage sponsor needs a commercial-scale answer immediately.

But understanding the likely path can prevent surprises later.

CDMO availability changes.

A facility that has capacity today may fill that capacity with another project.

A manufacturing slot discussed during an introductory call may not still be available several months later.

That is why capacity information should be treated as time-sensitive.

Sponsors should verify availability directly with the CDMO as the sourcing process progresses.

The closer the program gets to selection and contracting, the more specific that confirmation should become.

This is especially important when using CDMO directories or sourcing databases.

Capabilities such as modality or equipment may remain relatively stable.

Manufacturing availability can change much faster.

A static statement that a CDMO "has capacity" can become outdated quickly.

Capacity information is therefore most useful when it is:

• recent
• facility-specific
• project-specific
• confirmed by the manufacturer

Sponsors should be cautious about making project decisions based on old availability information.

The exact questions depend on the project, but a useful capacity discussion may cover:

Project kickoff

When could the project team realistically begin work?

Development work

How much development or technical-transfer work is required before manufacturing?

Manufacturing slot

When is the first realistic manufacturing slot?

Equipment availability

Is the required equipment available during that period?

Analytical resources

Will testing and analytical work become a bottleneck?

Raw materials

Are there long-lead materials or components that could delay the schedule?

Quality review

What quality or documentation activities need to occur before execution?

Schedule flexibility

What happens if the sponsor or CDMO misses a milestone?

Future batches

If the first batch succeeds, how easy will it be to schedule subsequent manufacturing?

These questions help turn the word “capacity” into an actual project timeline.

A manufacturing timeline is rarely completely fixed.

Sponsors should try to understand what could move it.

Potential scheduling risks can include:

• another customer occupying the suite longer than expected
• raw-material delays
• analytical delays
• development work taking longer than planned
• failed engineering runs
• equipment maintenance
• deviations
• staffing limitations
• sponsor delays in providing materials or documentation

No CDMO can eliminate every source of uncertainty.

A useful partner should be able to explain the assumptions behind the proposed schedule.

Another practical question is:

When does the manufacturing slot become real?

A CDMO may discuss an approximate slot during business-development conversations, but a sponsor may need to sign an agreement, issue a purchase order, make a deposit, or complete certain technical milestones before the slot is formally reserved.

Sponsors should understand:

• how slots are reserved
• whether deposits are required
• cancellation terms
• rescheduling rules
• what happens if technical transfer is delayed
• whether the slot can be lost

These details can materially affect the development plan.

The fastest available CDMO may not be the right technical partner.

Likewise, the technically strongest manufacturer may not be practical if the project would be delayed by a year.

The sponsor has to balance:

technical fit + facility fit + capacity + timing + risk

That tradeoff will differ by program.

A program facing a hard clinical milestone may place more weight on timing.

A program with greater schedule flexibility may prioritize specialized technical expertise.

For important programs, sponsors may want to understand alternatives before they are urgently needed.

That does not always mean qualifying two manufacturers in parallel.

It can simply mean knowing:

• which other CDMOs appear technically relevant
• where alternative capacity might exist
• what would be required to transfer the project
• how dependent the program is on a single facility

The right redundancy strategy depends on stage, budget, product, and supply risk.

But a broader view of the manufacturing market can be valuable when timelines are tight.

Capacity discussions become easier when each potential partner is asked similar questions.

For example:

The goal is not to force every manufacturer into the same operating model.

It is to make the differences visible.

Capacity should usually enter the process after basic technical relevance has been established.

A practical sequence is:

1. Define requirements→
2. find potential CDMOs→
3. confirm technical fit→
4. identify relevant facilities→
5. discuss capacity and timing→
6. compare options→
7. conduct deeper diligence→
8. select

There is little value in negotiating a manufacturing slot with a company that cannot support the project technically.

There is also little value in spending months diligencing a manufacturer that cannot support the required timeline.

Both questions matter.

Pharma Connect Navigator helps sponsors identify and compare manufacturing partners based on the requirements of their program.

Capacity and availability are important parts of CDMO selection, but they are also highly time-sensitive.

Sponsors should confirm current availability directly with the manufacturer before making a decision.

PCN's sourcing workflow helps teams narrow the market, identify relevant facilities, compare project fit, and move into conversations with manufacturers worth investigating.

As PCN's capacity and availability functionality is expanded, it is intended to support post-match diligence without changing the underlying Match % or turning temporary availability into a universal quality signal.

Current project timing and manufacturing availability should still be verified with the CDMO.

A strong CDMO selection process does not ask only:

Who has an open slot?

It asks:

Which technically relevant partner can realistically support our program on a timeline we can work with?

That is a more useful question.

Capacity matters because the manufacturing plan has to work in the real world, not just on paper.